Drug discrimination in human postaddicts: agonist-antagonist opioids

KL Preston, GE Bigelow, WK Bickel and IA Liebson

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Francis Scott Key Medical Center, Baltimore, Maryland.

To assess the stimulus properties of opioid mixed agonist-antagonist drugs in humans, postaddict volunteers were trained in a three-choice drug discrimination procedure to discriminate among the effects of i.m. given saline (4 ml), hydromorphone (3 mg/70 kg) and pentazocine (45 mg/70 kg). Subjects earned monetary reinforcement by correctly identifying the training drugs by letter code. Other subjective, behavioral and physiological measures were also collected. After training, subjects were tested for their ability to discriminate between the three drugs; generalization curves for the training drugs and three mixed agonist-antagonist test drugs (butorphanol, nalbuphine and buprenorphine) were then determined. In generalization testing both hydromorphone and pentazocine produced dose-related increases in drug- appropriate responses and in characteristic subjective effects measures. Butorphanol produced dose-related increases in identifications as pentazocine and in those subjective effect measures increased by pentazocine. Nalbuphine was not consistently identified as either pentazocine or hydromorphone and produced relatively flat dose- response functions on most of the subjective effect measures. At the three highest doses tested buprenorphine was identified in 50% of trials as hydromorphone and in 50% of trials as pentazocine in the discrimination measures and increased subjective effect scales which were characteristic of both hydromorphone and pentazocine. The results are most consistent with butorphanol having the stimulus properties of a kappa agonist and both nalbuphine and buprenorphine having the stimulus properties of partial mu agonists although the profiles of observed drug effects were complicated and not entirely consistent with a simple mu/kappa opioid receptor model.

Volume 250, Issue 1, pp. 184-196, 07/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				C.-S. Yuan, H. Doshan, M. R. Charney, M. O'Connor, T. Karrison, S. A. Maleckar, R. J. Israel, and J. Moss Tolerability, Gut Effects, and Pharmacokinetics of Methylnaltrexone Following Repeated Intravenous Administration in Humans J. Clin. Pharmacol., May 1, 2005; 45(5): 538 - 546. [Abstract] [Full Text] [PDF]

				T. H. Kelly, W. W. Stoops, A. S. Perry, M. A. Prendergast, and C. R. Rush Clinical Neuropharmacology of Drugs of Abuse: A Comparison of Drug-Discrimination and Subject-Report Measures Behav Cogn Neurosci Rev, December 1, 2003; 2(4): 227 - 260. [Abstract] [PDF]

				C.-S. Yuan, G. Wei, J. F. Foss, M. O'Connor, T. Karrison, and J. Osinski Effects of Subcutaneous Methylnaltrexone on Morphine-Induced Peripherally Mediated Side Effects: A Double-Blind Randomized Placebo-Controlled Trial J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 118 - 123. [Abstract] [Full Text] [PDF]

				K. L. Preston and G. E. Bigelow Effects of Agonist-Antagonist Opioids in Humans Trained in a Hydromorphone/Not Hydromorphone Discrimination J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 114 - 124. [Abstract] [Full Text]

				S. S. Negus and N. K. Mello Opioid Antinociception in Ovariectomized Monkeys: Comparison with Antinociception in Males and Effects of Estradiol Replacement J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1132 - 1140. [Abstract] [Full Text]

				J. A. Vivian, M. B. DeYoung, T. L. Sumpter, J. R. Traynor, J. W. Lewis, and J. H. Woods kappa -Opioid Receptor Effects of Butorphanol in Rhesus Monkeys J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 259 - 265. [Abstract] [Full Text]

				H. E. Jones, G. E. Bigelow, and K. L. Preston Assessment of Opioid Partial Agonist Activity with a Three-Choice Hydromorphone Dose-Discrimination Procedure J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1350 - 1361. [Abstract] [Full Text]

				J. P. Zacny, J. L. Hill, M. L. Black, and P. Sadeghi Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Pentazocine and Morphine in Normal Volunteers J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1197 - 1207. [Abstract] [Full Text]

				T. E. Schlaepfer, E. C. Strain, B. D. Greenberg, K. L. Preston, E. Lancaster, G. E. Bigelow, P. E. Barta, and G. D. Pearlson Site of Opioid Action in the Human Brain: Mu and Kappa Agonists' Subjective and Cerebral Blood Flow Effects Am J Psychiatry, April 1, 1998; 155(4): 470 - 473. [Abstract] [Full Text]

				J. P. Zacny, K. Conley, and J. Galinkin Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Buprenorphine and Morphine in Healthy Volunteers J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1187 - 1197. [Abstract] [Full Text]

				M. K. Greenwald, M. L. Stitzer, and K. A. Haberny J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1154 - 1163. [Abstract] [Full Text]

				J. P. Zacny, K. Conley, and S. Marks Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Nalbuphine and Morphine in Healthy Volunteers J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1159 - 1169. [Abstract] [Full Text]

				D. M. Tomkins, S. V. Otton, N. Joharchi, N-Y. Li, R. F. Balster, R. F. Tyndale, and E. M. Sellers Effect of Cytochrome P450 2D1 Inhibition on Hydrocodone Metabolism and its Behavioral Consequences in Rats J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1374 - 1382. [Abstract] [Full Text]

				C. R. Rush, S. Madakasira, N. H. Goldman, W. L. Woolverton, and J. K. Rowlett Discriminative Stimulus Effects of Zolpidem in Pentobarbital-Trained Subjects: II. Comparison with Triazolam and Caffeine in Humans J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 174 - 188. [Abstract] [Full Text]